{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:42:37Z","timestamp":1788824557650,"version":"build-2803163510"},"reference-count":57,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007033","name":"Eisai Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007033","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lenvatinib is an oral multikinase inhibitor approved for use as first\u2010line treatment for patients with advanced hepatocellular carcinoma (HCC). However, like other agents in this drug class, lenvatinib is associated with clinically important adverse events (AEs) that could adversely affect patient outcomes. Hypertension, diarrhea, decreased appetite\/weight, hand\u2013foot skin reaction, and proteinuria are among the most common AEs associated with lenvatinib therapy. This article provides strategies for the effective management of lenvatinib\u2010associated AEs based on the expert opinion of authors and currently available literature. Due to the high risk of AEs in patients receiving lenvatinib, prophylactic measures and regular monitoring for AEs are recommended. Lenvatinib dose interruption, adjustment, or discontinuation of treatment may be required for patients who develop AEs. For grade 1 or 2 AEs, dose interruption is generally not required. For persistent or intolerable grade 2 or 3 AEs, lenvatinib treatment should be interrupted until symptoms improve\/resolve to grade 0\u20131 or baseline levels. Thereafter, treatment should be resumed at the same or a lower dose. Disease progression may occur in patients who do not initially respond to treatment or receive a suboptimal lenvatinib dose following dose reduction, resulting in lack of efficacy. Therefore, to derive maximum treatment benefit and ensure long\u2010term disease control, lenvatinib should be maintained at the highest possible dose when managing AEs. To conclude, lenvatinib\u2010associated AEs can be managed with prophylactic measures, regular monitoring and symptomatic management, which can ensure continued treatment and maximum survival benefit in patients with advanced HCC receiving first\u2010line lenvatinib therapy.<\/jats:p>","DOI":"10.1111\/jgh.15727","type":"journal-article","created":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T03:42:51Z","timestamp":1635824571000},"page":"428-439","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma"],"prefix":"10.1111","volume":"37","author":[{"given":"Bo Hyun","family":"Kim","sequence":"first","affiliation":[{"name":"Center for Liver and Pancreatobiliary Cancer National Cancer Center  Goyang Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Jong","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Liver Research Institute Seoul National University College of Medicine  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonseok","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Bum","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Chonnam National University Medical School  Gwangju Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Young","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, Kyungpook National University Kyungpook National University Hospital  Daegu Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9658-8050","authenticated-orcid":false,"given":"Seung Up","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Yonsei University College of Medicine  Seoul Republic of Korea"},{"name":"Yonsei Liver Center Severance Hospital  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8327-3439","authenticated-orcid":false,"given":"Do Young","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Yonsei University College of Medicine  Seoul Republic of Korea"},{"name":"Yonsei Liver Center Severance Hospital  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,11,17]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.019"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy308"},{"key":"e_1_2_8_4_1","unstructured":"NCCN(2020)NCCN clinical practice guidelines: hepatobiliary cancers(version 5.2020).https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hepatobiliary.pdf(Accessed 12 Jan 2021)."},{"key":"e_1_2_8_5_1","unstructured":"Lenvima USPrescribing information(2020). Available from:http:\/\/www.lenvima.com\/pdfs\/prescribing\u2010information.pdf(Accessed 5 March 2021)."},{"key":"e_1_2_8_6_1","unstructured":"European Medicines Agency(2020).LENVIMA (lenvatinib): summary of product characteristics.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/lenvima\u2010epar\u2010product\u2010information_en.pdf. Accessed 2 March 2021."},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1354"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-016-1263-4"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.917"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30207-1"},{"key":"e_1_2_8_11_1","unstructured":"European Medicines Agency(2018).LENVIMA (lenvatinib): assessment report.https:\/\/www.ema.europa.eu\/en\/documents\/variation\u2010report\/lenvima\u2010h\u2010c\u20103727\u2010ii\u20100011\u2010g\u2010epar\u2010assessment\u2010report\u2010variation_en.pdf. Accessed 2 March 2021."},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-020-00179-7"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12209"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071867"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i30.4465"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1159\/000508901"},{"key":"e_1_2_8_17_1","unstructured":"CelermajerY PrinceDS StrattonEet al.Real\u2010world safety and tolerability data for lenvatinib use in unresectable hepatocellular cancer. Presented at: American Association for the Study of Liver Diseases \u2010 The Liver Meeting Digital Experience; November 13\u201316 2020; virtual. Abstract 1167. Accessed 2 March 2021.https:\/\/www.aasld.org\/posters\/25569070\/"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15355"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.3_suppl.275"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000512239"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e16596"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.4_suppl.317"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq091"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2018.1530212"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-018-0708-8"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2019.11.009"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvz022"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12265-020-10024-5"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.04187"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu197"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.28.147"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.288"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.39"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60674-5"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2019.11.010"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0506-6"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41199-017-0026-0"},{"key":"e_1_2_8_38_1","unstructured":"Janssen\u2010Cilag Pvt Ltd. (2021).Imodium (loperamide): package insert.https:\/\/www.medicines.org.uk\/emc\/files\/pil.558.pdf. Accessed 2 March 2021."},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/783196"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.suponc.2010.12.007"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0131"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0237"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1548-5315(11)70385-0"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.6914"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjsports-2016-096422"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.17925\/EE.2020.16.1.32"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2018.07.003"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-013-0049-2"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.3109\/02841860902980453"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-009-9314-9"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijom.2019.07.010"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01307"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4564"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32453-9"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.17998\/jlc.2021.09.23"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jgh.15727","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jgh.15727","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jgh.15727","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T11:57:55Z","timestamp":1693137475000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jgh.15727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,17]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1111\/jgh.15727"],"URL":"https:\/\/doi.org\/10.1111\/jgh.15727","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,17]]},"assertion":[{"value":"2021-08-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}